Piper Sandler raised the firm’s price target on CytomX Therapeutics (CTMX) to $12 from $10 and keeps an Overweight rating on the shares. Updated Phase I data on varsetatug maseatecan in third line and later metastatic colorectal cancer showed dose-dependent efficacy with 10mg/kg achieving a 32% overall response rate and 84% disease control rate with immature median progression-free survival of 7.1 months. CytomX will report more mature data later this year.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CTMX:
- CytomX Therapeutics Raises $234 Million in Equity Offering
- CytomX Therapeutics price target raised to $16 from $10 at Barclays
- CytomX Therapeutics price target raised to $16 from $8 at Jefferies
- CytomX Therapeutics price target raised to $15 from $10 at Guggenheim
- CytomX Therapeutics 45.9M share Secondary priced at $5.30